We are live on !
Find out more
Affinity Asset Advisors Portfolio holdings
AUM
$2.21B
Turnover
29.69%
1-Year Est. Return
431.26%
This Fund
S&P 500
This Quarter Est. Return
+29.83%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$2.21B
AUM Growth
+$276M
(+14%)
Cap. Flow
-$34.2M
Cap. Flow % of AUM
Cap. Flow %
-1.55%
Top 10 Holdings %
Top 10 Hldgs %
39.41%
Holding
128
New
23
Increased
32
Reduced
32
Closed
15
Avg Time Held
Equity + Options
1
year
Top 10 Avg Time Held
Equity + Options
0.8
years
Top 20 Avg Time Held
Equity + Options
0.7
years
Avg Time Held Equity only
1.1
years
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
First Tracks Biotherapeutics
TRAX
|
+$38M |
| 2 |
Roivant Sciences
ROIV
|
+$28.1M |
| 3 |
Avalo Therapeutics
AVTX
|
+$24.6M |
| 4 |
Revolution Medicines
RVMD
|
+$21.9M |
| 5 |
Insmed
INSM
|
+$20.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$55.6M |
| 2 |
Arcellx
ACLX
|
+$41.7M |
| 3 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$34.2M |
| 4 |
Terns Pharmaceuticals
TERN
|
+$29.7M |
| 5 |
Apogee Therapeutics
APGE
|
+$26.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.73% |
| 2 | Miscellaneous | 9.21% |
| 3 | Financials | 1.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Belite Bio
BLTE
$5.93B
| $25.4M | 1.15% |
165,000
+100,000
| +154% | +$15.3M |
2025 Q4
2 quarters
|
|
27
Enliven Therapeutics
ELVN
$3.04B
| $25.4M | 1.15% |
500,000
-86,904
| -15% | -$3.69M |
2026 Q1
1 quarter
|
|
28
DELISTED
Forte Biosciences
FBRX
| $24.3M | 1.1% |
1,145,391
+133,501
| +13% | +$3.17M |
2025 Q4
2 quarters
|
|
29
CALL
Eli Lilly
LLY
$1.14T
| $24M | 1.08% |
+20,000
| New | +$20.4M |
2026 Q2
0 quarters
|
|
30
Nurix Therapeutics
NRIX
$2.77B
| $23.5M | 1.06% |
967,620
| – | – |
2022 Q4
14 quarters
|
|
31
Alto Neuroscience
ANRO
$862M
| $22.4M | 1.01% |
850,000
+350,000
| +70% | +$8.09M |
2026 Q1
1 quarter
|
|
32
Madrigal Pharmaceuticals
MDGL
$10B
| $21.5M | 0.97% |
40,000
-15,000
| -27% | -$7.68M |
2021 Q4
18 quarters
|
|
33
Protagonist Therapeutics
PTGX
$8.96B
| $21.1M | 0.95% |
172,125
| – | – |
2024 Q4
6 quarters
|
|
34
Mineralys Therapeutics
MLYS
$1.82B
| $20.2M | 0.91% |
750,000
| – | – |
2024 Q1
9 quarters
|
|
35
Relay Therapeutics
RLAY
$3.98B
| $19.6M | 0.89% |
1,050,000
+650,000
| +163% | +$9.44M |
2026 Q1
1 quarter
|
|
36
Sagimet Biosciences
SGMT
$679M
| $19.3M | 0.87% |
2,497,864
+1,629,844
| +188% | +$11.1M |
2025 Q3
3 quarters
|
|
37
Jade Biosciences
JBIO
$928M
| $18.7M | 0.84% |
840,350
+200,394
| +31% | +$4.18M |
2024 Q2
8 quarters
|
|
38
Cogent Biosciences
COGT
$5.42B
| $17.4M | 0.79% |
450,000
-300,000
| -40% | -$10.5M |
2025 Q4
2 quarters
|
|
39
Travere Therapeutics
TVTX
$4.72B
| $17M | 0.77% |
300,000
| – | – |
2024 Q4
6 quarters
|
|
40
Cullinan Oncology
CGEM
$925M
| $15.9M | 0.72% |
875,760
+94,500
| +12% | +$1.4M |
2023 Q4
10 quarters
|
|
41
Savara
SVRA
$867M
| $15.5M | 0.7% |
2,512,153
| – | – |
2025 Q2
4 quarters
|
|
42
IDEAYA Biosciences
IDYA
$3.35B
| $14.9M | 0.67% |
+400,000
| New | +$12.2M |
2026 Q2
0 quarters
|
|
43
Perspective Therapeutics
CATX
$184M
| $14.4M | 0.65% |
4,214,582
+1,050,000
| +33% | +$3.97M |
2024 Q1
9 quarters
|
|
44
Odyssey Therapeutics
ODTX
$942M
| $14.3M | 0.65% |
+766,346
| New | +$13.4M |
2026 Q2
0 quarters
|
|
45
PUT
Omeros
OMER
$1.2B
| $13.4M | 0.61% |
+1,411,300
| New | +$16.8M |
2026 Q2
0 quarters
|
|
46
Helix Acquisition Corp III
HLXC
$227M
| $13.3M | 0.6% |
1,250,000
| – | – |
2026 Q1
1 quarter
|
|
47
Equillium
EQ
$78M
| $13.1M | 0.59% |
4,100,000
+2,873,690
| +234% | +$6.89M |
2026 Q1
1 quarter
|
|
48
CALL
Alkermes
ALKS
$7.32B
| $13.1M | 0.59% |
+250,000
| New | +$9.8M |
2026 Q2
0 quarters
|
|
49
Establishment Labs
ESTA
$1.9B
| $12.7M | 0.57% |
148,013
+48,013
| +48% | +$3.45M |
2021 Q1
21 quarters
|
|
50
Climb Bio
CLYM
$585M
| $12.7M | 0.57% |
972,000
+272,000
| +39% | +$2.81M |
2024 Q2
8 quarters
|
|
Similar funds
Affinity Asset Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Affinity Asset Advisors held 128 positions worth $2.21B, up 14% from $1.94B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Affinity Asset Advisors's Q2 2026 filing shows 23 new, 32 increased, 32 reduced and 15 closed positions. Its largest new stake was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M. The largest sale was Centessa Pharmaceuticals, an estimated $55.6M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Financials.
- Affinity Asset Advisors's largest Q2 2026 buy was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M.
- Affinity Asset Advisors added most to Roivant Sciences in Q2 2026, an estimated $28.1M increase.
- Affinity Asset Advisors's biggest Q2 2026 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $34.2M.
- Affinity Asset Advisors fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $55.6M.
- Affinity Asset Advisors's ten largest holdings make up 39% of its $2.21B portfolio in Q2 2026.
- Affinity Asset Advisors opened 23 new positions and closed 15 in Q2 2026.
- Affinity Asset Advisors's portfolio value rose 14% quarter-over-quarter to $2.21B.
Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.